Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018)

Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno, Carmine Pinto, Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno, Carmine Pinto

Abstract

Background: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Generally, tumors co-opt the programmed death-1/ligand 1 (PD-1/PD-L1) signaling pathway as one key mechanism to evade immune surveillance. As today, anti-PD-1 monoclonal antibodies are FDA approved only for DNA mismatch repair deficient/microsatellite instability-high (MMRd/MSI-H), which represent only about 5% among all mCRC. Nowadays, there are no data demonstrating anti PD-1 activity in proficient and stable disease (MMRp/MSS). A different target in mCRC is also the Vascular Endothelial Growth Factor A (VEGF-A), which acts on endothelial cells to stimulate angiogenesis. VEGF-A inhibition with bevacizumab has shown to increase the immune cell infiltration, providing a solid rationale for combining VEGF targeted agents with immune checkpoint inhibitors. Based on these evidences, we explore the combination of triplet chemotherapy (FOLFOXIRI) with bevacizumab and nivolumab in pts. with mCRC RAS/BRAF mutant regardless of microsatellite status.

Methods/design: This is a prospective, open-label, multicentric phase II trial where pts. with mCRC RAS/BRAF mutated, in first line will receive nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks. Bevacizumab will be administered intravenously at dose of 5 mg/kg every 2 weeks and nivolumab intravenously as a flat dose of 240 mg every 2 weeks. The primary endpoint is the overall response rate (ORR). This study hypothesis is that the treatment is able to improve the ORR from 66 to 80%. Secondary endpoints include OS, safety, time to progression, duration of response. Collateral translational studies evaluate the i) tumor mutational burden, and ii) genetic alterations by circulating free DNA (cfDNA) obtained from plasma samples. The trial is open to enrollment, 9 of planned 70 pts. have been enrolled.

Trial registration: NIVACOR is registered at ClinicalTrials.gov: NCT04072198 , August 28, 2019.

Keywords: FOLFOXIRI Bevacizumab; First line therapy; Metastatic colorectal Cancer; Nivolumab.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Study Design. Primary Endpoint: Overall Response Rate (ORR) per investigator assessment (RECIST v1.1). *SD: stable disease, RP: partial response, RC: complete response

References

    1. National Cancer Institute Surveillance, Epidemiology, and end results program. SEER Stat Fact Sheets: Colon and Rectum Cancer. . Accessed 3 Mar 2016.
    1. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi: 10.1038/nm.3967.
    1. Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92. doi: 10.1038/nrc.2016.126.
    1. Fiala O, Buchler T, Mohelnikova-Duchonova B, et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2016;37:6823–6830. doi: 10.1007/s13277-015-4523-7.
    1. Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13–21. doi: 10.1093/annonc/mdu378.
    1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766.
    1. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103. doi: 10.1038/nature10868.
    1. Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–1475. doi: 10.1016/j.ejca.2012.02.057.
    1. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal Cancer. N Engl J Med. 2014;371:1609–1618. doi: 10.1056/NEJMoa1403108.
    1. Hurwitz H, Tan BR, Reeves JA, et al. Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC) J Clin Oncol. 2017;35:657. doi: 10.1200/JCO.2017.35.4_suppl.657.
    1. Schmoll HJ, Meinert FM, Cygon F, et al. “CHARTA”: FOLFOX/bevacizumab vs. FOLFOXIRI/ bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO. J Clin Oncol. 2017;35(15 suppl):3533. doi: 10.1200/JCO.2017.35.15_suppl.3533.
    1. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315. doi: 10.1016/S1470-2045(15)00122-9.
    1. Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401-11. 10.1200/JCO.19.01340.
    1. Geissler M, Tannapfel A, Reinacher-Schick A, et al. Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI 1 Panitumumab versus FOLFOXIRI as first- line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC). Abstract PD-030. Ann Oncol. 2019:iv119. 10.1093/annonc/mdz156.
    1. Mlecnik B, Bindea GG, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711. doi: 10.1016/j.immuni.2016.02.025.
    1. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Ann Oncol. 2016;27:1492–1504. doi: 10.1093/annonc/mdw217.
    1. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733.
    1. Le DT, Kavan P, Kim TW, et al. KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Presented at: American Society of Clinical Oncology; June 1–5, 2018; Chicago, IL. 2018.
    1. Diaz L, Marabelle A, Kim TW, et al. Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Presented at: European Society for Medical Oncology; September 8–12, 2017; Madrid, Spain. 2017.
    1. Shahda S, Noonan AM, Bekaii-Saab TS, et al. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal. Presented at: American Society of Clinical Oncology; June 2–6, 2017; Chicago. IL. 2017.
    1. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–1191. doi: 10.1016/S1470-2045(17)30422-9.
    1. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/ microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–779. doi: 10.1200/JCO.2017.76.9901.
    1. Grothey A, Tabernero J, Arnold D et al. Fluoropyrimidine (FP) and bevacizumab + atezolizumab as first-line treatment for BRAFwt metastatic colorectal cancer: Findings from the MODUL trial of biomarker-driven maintenance. Presented at: European Society for Medical Oncology; October 19–23, 2018; Munich, Germany. 2018; abstract LBA19.
    1. Hochster HS, Bendell JC, Cleary JM et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19–21, 2017; San Francisco, CA. 2017; abstract 673.
    1. Bendell JC, Powderly JD, Lieu CH et al. Safety and efficacy of MPDL320A (anti-PDL1) in combination with bevacizumab (bev)and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: American Society of Clinical Oncology; May 29 June, 2015; Chicago, IL 2015; abstract 704.
    1. An Investigational immunotherapy study of Nivolumab with standard of care therapy vs standard of care therapy for first line treatment of colorectal cancer that has spread (CheckMate 9X8). .
    1. An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142). .
    1. NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in microsatellite stable, MGMT Silenced Metastatic Colorectal Cancer (MAYA) .
    1. A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW). .
    1. Study of pembrolizumab (MK-3475) vs standard therapy in partecipants with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (MK-3475-177/KEY-NOTE-177). .
    1. Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients. NCT03626922. .
    1. Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study. .
    1. Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer. .
    1. Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO). .
    1. Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer. .
    1. Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer. .
    1. Fumet JD, Isambert N, Hervieu A, et al. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open. 2018;3:e000375. doi: 10.1136/esmoopen-2018-000375.
    1. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 1998;160:1224–1232.
    1. Gabrilovich D, Ishida T, Oyama T, Ran S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150–4166. doi: 10.1182/blood.V92.11.4150.
    1. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy, Proc. Natl Acad Sci U S A. 2012;109:17561–17566. doi: 10.1073/pnas.1215397109.
    1. Becht E, de Reynies A, Giraldo NA, Pilati C, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016;22:4057–4066. doi: 10.1158/1078-0432.CCR-15-2879.
    1. Tian L, Goldstein A, Wang H, Ching Lo H, et al. Mutual regulation of tumor vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250-4. 10.1038/nature21724.
    1. Borgstrom P, Hughes GK, Hansell P, et al. Leukocyte adhesion in angiogenic blood vessels role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. J Clin Invest. 1997;99(9):2246–53. 10.1172/JCI119399.
    1. Balar AV, Galsky MD, Rosenberg JE, Powles T, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-20.
    1. Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): preliminary safety and efficacy results. Annals of Oncology. 2016;27(6):266-95. 10.1093/annonc/mdw373.
    1. Amin AERP, R. Infante J, Ernstoff SM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15_suppl):5010. 10.1200/jco.2014.32.15_suppl.5010.
    1. Wallin JC, Bendell R, Funke M, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. 10.1038/ncomms12624.
    1. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-46. 10.1016/S0140-6736(16)00587-0.
    1. Reck MS, Cappuzzo F, Orlandi F, et al. Primary PFS and safety analyses of a randomized Phase III study of carboplatin+paclitaxel +/− bevacizumab, with or without Atezolizumab in 1L non squamous metastatic NSCLC (IMpower150). ESMO Immuno Oncology Congress. 2017; Abstract 204. .
    1. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301. 10.1056/NEJMoa1716948.
    1. Galluzzi L, Buque A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690-714. 10.1016/j.ccell.2015.10.012.
    1. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343-54. 10.1016/j.immuni.2015.11.024.
    1. Vincent J, Mignot G, Chalmin F, et al. F. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052-61. 10.1158/0008-5472.CAN-09-3690.
    1. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482-91. 10.1038/onc.2009.356.
    1. Dosset M, Vargas TR, Lagrange A, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. ONCOIMMUNOLOGY. 2018;7(6):e1433981. doi: 10.1080/2162402X.2018.1433981.
    1. Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/Tipiracil plus Oxaliplatin improves PD-1 blockade in colorectal Cancer by inducing immunogenic Cella death and depleting macrophages. Cancer Immunol Res. 2019;7:1958–1969. doi: 10.1158/2326-6066.CIR-19-0228.
    1. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757. doi: 10.1038/s41591-018-0053-3.
    1. Motzer RJ, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs. sunitinib in untreated metastatic renal cell carcinoma (mRCC) J Clin Oncol. 2018;36(6):578. doi: 10.1200/JCO.2018.36.6_suppl.578.
    1. Hodi FS, Lawrance D, Lezcano C, et al. Bevacizumab plus Ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–642. doi: 10.1158/2326-6066.CIR-14-0053.
    1. Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol. 2015;33(Suppl. S3):704. doi: 10.1200/jco.2015.33.3_suppl.704.
    1. Shahda S, Noonan AM, Bekaii-Saab TS, et al. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. J Clin Oncol. 2017;35(15):3541. doi: 10.1200/JCO.2017.35.15_suppl.3541.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner